The United States trajectory offers an instructive precedent for European commercial teams. The FDA granted tentative approval to generic semaglutide injection submissions from Apotex and Orbicular ahead of US patent expiry, and the first generic liraglutide for weight loss received full FDA approval in August 2025. Novo Nordisk's strategy in the face of approaching exclusivity loss, within a market still effectively a two-company duopoly with Eli Lilly, centres on differentiation: the oral formulation of semaglutide, approved in the US in December 2025 and recommended for European approval in May 2026, represents a next-generation asset designed to maintain market leadership through reformulation rather than price competition. Eli Lilly's orforglipron, a small-molecule non-peptide agent approved by the FDA in April 2026, is structurally distinct from peptide-based biosimilar competitors; a molecule that cannot itself become a biosimilar in the traditional sense, giving Lilly a product architecture that sidesteps the conventional exclusivity cliff.
Commercial Defence Strategies Before the European Patent Cliff Arrives
European patent expiry for semaglutide is not imminent, but the commercial strategies required to defend branded value ahead of that cliff are being built now. The window available to Novo Nordisk and other incumbents with European exclusivity is one in which to establish label breadth, clinical guidelines, reimbursement positions, patient adherence infrastructure, and market access frameworks that will be materially harder to replicate through biosimilar pathways than the molecule itself. Each new indication added to a branded GLP-1 therapy, whether cardiovascular risk reduction, metabolic dysfunction-associated steatohepatitis, obstructive sleep apnoea, or other conditions in Phase III development, creates an additional layer of differentiation that follow-on therapies must match through their own clinical development programmes.
For biosimilar developers, the European GLP-1 market presents a structurally different opportunity from the small-molecule generics market they may have previously operated in: one where originators, including Copenhagen neighbour Zealand Pharma under its “Metabolic Frontier 2030” strategy, are simultaneously advancing next-generation assets such as CagriSema and MariTide to reset the competitive baseline before biosimilar entry even arrives. Manufacturing complexity, regulatory classification uncertainty, and the challenge of achieving formulary positioning against branded products backed by established real-world evidence programmes all raise the barriers to profitable market entry. Statutory health insurers, hospital pharmacy networks, and employer benefit managers across Europe will be the main buyers when biosimilar options become available, and the tendering and formulary mechanisms for this class are not yet established. Obesity Therapies Europe 2027 brings together originator commercial teams, biosimilar developers, payers, and market access consultants to examine these strategic decisions ahead of the European patent inflection.
